Tag Archives: John Newman

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and Cassava Sciences (NASDAQ: SAVA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Cassava Sciences (SAVA – Research Report) with bullish sentiments. Regeneron (REGN) Canaccord Genuity analyst John Newman

Palatin Technologies (PTN) Receives a Buy from Canaccord Genuity

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Palatin Technologies (PTN – Research Report), with a price target of $3.00. The company’s shares closed last Wednesday at $0.92. According to TipRanks.com, Newman is

Canaccord Genuity Initiates a Buy Rating on Ocuphire Pharma (OCUP)

Ocuphire Pharma (OCUP – Research Report) received a Buy rating and a $22.00 price target from Canaccord Genuity analyst John Newman today. The company’s shares closed last Tuesday at $10.57. According to TipRanks.com, Newman is a 5-star analyst with an

Analysts Are Bullish on Top Healthcare Stocks: Sesen Bio (SESN), Arena Pharma (ARNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sesen Bio (SESN – Research Report) and Arena Pharma (ARNA – Research Report) with bullish sentiments. Sesen Bio (SESN) Canaccord Genuity analyst

Canaccord Genuity Sticks to Its Buy Rating for Selecta Biosciences (SELB)

Canaccord Genuity analyst John Newman maintained a Buy rating on Selecta Biosciences (SELB – Research Report) yesterday and set a price target of $13.00. The company’s shares closed last Wednesday at $3.16. According to TipRanks.com, Newman is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (NASDAQ: MCRB), Karyopharm Therapeutics (NASDAQ: KPTI) and Biodesix (NASDAQ: BDSX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seres Therapeutics (MCRB – Research Report), Karyopharm Therapeutics (KPTI – Research Report) and Biodesix (BDSX – Research Report) with bullish sentiments. Seres